A Phase III Long Term Study of K-877 Extended Release Tablet

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

June 13, 2022

Study Completion Date

June 13, 2022

Conditions
Dyslipidemias
Interventions
DRUG

K-877 ER 0.2 mg/day morning administration (once daily)

K-877 ER 0.2 mg tablet

DRUG

K-877 ER 0.2 mg/day evening administration (once daily)

K-877 ER 0.2 mg tablet

Trial Locations (14)

Unknown

Saiseikai Futsukaichi Hospital, Fukuoka

National Hospital Organization Takasaki General Medical Center, Gunma

Hasegawa Medicine Clinic, Hokkaido

Japan Community Health care Organization Hokkaido Hospital, Hokkaido

Minami Akatsuka Clinic, Ibaraki

Saiseikai Yokohamashi Nanbu Hospital, Kanagawa

Kinugawa Cardiology Clinic, Osaka

Kyosokai AMC NISHI-UMEDA Clinic, Osaka

Medical corporation Tani clinic, Osaka

Shiraiwa medical clinic, Osaka

Cosmos medical corporation Aozora total clinic, Saitama

Akasaka Chuou Clinic, Tokyo

Medical Corporation Chiseikai Tokyo Center Clinic, Tokyo

Shimokitazawa Tomo Clinic, Tokyo

All Listed Sponsors
lead

Kowa Company, Ltd.

INDUSTRY

NCT04716595 - A Phase III Long Term Study of K-877 Extended Release Tablet | Biotech Hunter | Biotech Hunter